The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
https://doi.org/10.14412/1995-4484-2019-564-57
Abstract
Rheumatoid arthritis (RA) is an immune-mediated inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis (synovitis) and systemic damage of internal organs and leads to early disability and shorter life expectancy in patients. Much attention is paid to studying the role of interleukin 6 (IL6) in the spectrum of proinflammatory cytokines involved in the pathogenesis of RA. The clinical introduction of anti-IL receptor monoclonal antibodies, such as tocilizumab and sarilumab, that inhibit the activity of this cytokine, is an important step in the improvement of RA treatment. The review considers the data from the main randomized controlled trials of the efficacy and safety of sarilumab in RA and discusses the prospects for using the drug to treat this disease.
About the Authors
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522; 8, Trubetskaya St., Build. 2, Moscow 119991.
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya St., Build. 1, Moscow 125993.
References
1. Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290-331 (In Russ.).
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Eng J Med. 2012;365:2205-19. doi: 10.1056/NEJMra1004965
3. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 22;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8
4. Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013 (In Russ.).
5. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338-48. doi: 10.1016/S0140-6736(17)31491-5
6. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.). doi: 10.14412/1995-4484-2017-409-419
7. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555
8. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-37. doi: 10.1016/S0140-6736(17)31472-1
9. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;15:448-57. doi: 10.1038/ni1117-1271b
10. Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.). doi: 10.14412/1995-4484-2017-590-599
11. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17(6):395-412. doi: 10.1038/nrd.2018.45
12. Rubbert-Roth A, Furst DE, Nebesky JM, et al. A review of recent advances using tocilizumab in the treatment of rheumatic diseases. Rheumatol Ther. 2018;5(1):21-42. doi: 10.1007/s40744-018-0102-x
13. Lamb YN, Deeks ED. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis. Drugs. 2018;78(9):929-40. doi: 10.1007/s40265-018-0929-z
14. McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(3):61-7. doi: 10.1177/1759720X17752037
15. Genentech Inc. Actemra (package insert). California: Genentech Inc, https://www.gene.com/download/pdf/actemra_prescribing.pdf (2017, accessed 15 September 2017).
16. Regeneron Pharmaceuticals Inc / Sanofi-aventis US LLC. Kevzara (package insert). New York/New Jersey: Regeneron Pharmaceuticals Inc / Sanofi-aventis US LLC, http://products.sanofi.us/kevzara/kevzara.pdf (2017, accessed 10 September 2017).
17. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results for the randomized SARIK-RA-MOBILITY part A trial. Ann Rheum Dis. 2014;73:1626-34. doi: 10.1136/annrheumdis-2013-204405
18. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum. 2015;67:1424-37. doi: 10.1002/art.39093
19. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum. 2017;69:277-90. doi: 10.1002/art.39944
20. Burmester GR, Lin YL, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomized, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840-7. doi: 10.1136/annrheumdis-2016-210310
21. Wells AF, Parrino J, Mangan EK, et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol Ther. 2019 May 14. doi: 10.1007/s40744-019-0157
22. Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018 Dec 19. doi: 10.1093/rheumatology/key361
23. Genovese MC, van Adelsberg J, Fan C, et al.; EXTEND study investigators. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018;57(8):1423-31. doi: 10.1093/rheumatology/key121
24. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37. doi: 10.1002/art.21519
25. Emery P, Pope JE, Kruger K, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535-63. doi: 10.1007/s12325-018-0757-2
26. Burmester GR, St John G, Iglesias-Rodrigues M, et al. Switching from adalimumab to sarilumasb is associated with comparable efficacy bit lower functional improvement versus comtinous earilumab monotherapy thtough 48-week open-label extension (OLE) of the phase III MONARCH rial. Ann Rheum Dis. 2018;77(Suppl 2):952-3. doi: 10.1136/annrheumdis-2018-eular.1372
27. Tanaka Y, Wada K, Takahashi Y, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi: 10.1186/s13075-019-1856-4
28. Kameda H, Wada K, Takahashi Y, et al. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Mod Rheumatol. 2019 Jul 24. doi: 10.1080/14397595.2019.1639939
29. Genovese MC, Fleischmann R, Mangan E, et al. Efficacy and safety of Sarilumab in subgroups of patients with rheumatoid arthritis from 2 phase 3 studies [abstract]. Arthritis Rheum. 2016;68(suppl 10). Available from: https://acrabstracts.org/abstract/efficacy-and-safety-of-sarilumab-in-subgroups-of-patients-with-rheumatoid-arthritis-from-2-phase-3-studies/
30. Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarikumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019;5:e000887. doi: 10:1136/rmdopen-2018-000887
31. Burmester GR, Lin Y, St John G, et al. Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARD in patients with rheumatoid arthritis. Ann Rheum Dis. 2018. doi: 10.1136/qnnrheumdis-20180eular.SAT0172
32. Curtis JR, Lin Y, Thangsvelu K, et al. Withdrawal of conventional synthetic disease-modifying antitheumatic drugs in the sarilumab open-label EXTEND study: efficacy and safety analysis. Ann Rheum Dis. 2019;78(Suppl 2):702-3. doi: 10.1136/annrheumdis-2019-eular.740
33. Emery P, van Hoogstraten H, Jayawardena S, et al. Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab [abstract]. Available from: https://acrabstracts.org/abstract/efficacy-of-sarilumab-in-patients-with-rheumatoid-arthritis-who-previously-received-sarilumab-or-tocilizumab/
34. Vershueren P, Emery P, van Hoogstraten H, et al. Efficaсy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. Ann Rheum Dis. 2018;77(Suppl.2):327. https://doi.org/10.1136/annrheumdis-2018-eular.1376
35. Nasonov EL, Stanislav ML, Raskina TA, et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):142-8 (In Russ.). doi: 10.14412/1995-4484-2019-142-148
36. Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
37. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019
38. Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018;38(6):935-47. doi: 10.1007/s00296-018-4005-5
39. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol. 2010;28:S32-40.
40. Rendas-Baum R, Bayliss M, Kosinski M, et al. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient's perspective. Curr Med Res Opin. 2014;30:1391-403. doi: 10.1185/03007995.2014.896328
41. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123-30. doi: 10.1016/j.semarthrit.2014.05.001
42. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):263-71 (In Russ.). doi: 10.14412/1995-4484-2018-263-271
43. Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885-95. doi: 10.1093/rheumatology/kex391
44. Karateev AE, Nasonov EL. Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):197-209 (In Russ.). doi: 10.14412/1995-4484-2019-197-209
45. Lisitsyna TA, Veltishchev DYu, Seravina OF, et al. Proinflammatory cytokines and depression in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):261-6 (In Russ.). doi: 10.14412/1995-4484-2013-1498
46. Lisitsyna TA, Veltishchev DYu, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):318-27 (In Russ.). doi: 10.14412/1995-4484-2019-318-32747.
47. Crotti C, Biggioggero M, Becciolini A, Favalli EG. Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Relat Outcome Meas. 2018;9:275-84. doi: 10.2147/PROM.S147286
48. Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:19. doi: 10.1186/s13075-016-1096-9
49. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43(7):1478-87. doi: 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M
50. Gossec L, Strand V, Proudfoot C, et al. Effects of Sarilumab on rheumatoid arthritis as reported by patients using the rheumatoid arthritis impact of disease scale. J Rheumatol. 2019 Mar 15. doi: 10.3899/jrheum.180904
51. Dougados M, Brault Y, Logeart I, et al. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012;14(3):R129. doi: 10.1186/ar3859
52. Gullick NJ, Scott DL. Rheumatoid arthritis: clinical utility of the RAID (RA Impact of Disease) score. Nat Rev Rheumatol. 2011;7:499-500. doi: 10.1038/nrrheum.2011.105
53. Heiberg T, Austad C, Kvien TK, Uhlig T. Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:1080-2. doi: 10.1136/ard.2010.143032
54. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the Rheumatoid Arthritis Impact of Disease score, a patient-derived composite measure of impact of rheumatoid arthritis: A EULAR initiative. Ann Rheum Dis. 2011;70:935-42. doi: 10.1136/ard.2010.142901
55. Strand V, Gossec L, Proudfoot CWJ, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):129. doi: 10.1186/s13075-018-1614-z
56. Gossec L, Boklage S, St John G, et al. Pain is improved in around 50% of patients and fatigue in 40% of patients with rheumatoid arthritis treated with sarilumab in the target, mobility and monarch trials [abstract]. Arthritis Rheum. 2018;70(suppl 10). Available from: https://acrabstracts.org/abstract/pain-is-improved-in-around-50-of-patients-and-fatigue-in-40-of-patients-with-rheumatoid-arthritis-treated-with-sarilumab-in-the-target-mobility-and-monarch-trials/
57. Choy E, Freemantle N, Proudfoot C, et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798
58. Choy E, Freemantle N, Proudfoot C, et al. Indirect treatment comparison of the efficacy and safety of Sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther. 2019;36(4):817-27. doi: 10.1007/s12325-019-00912-x
59. Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18:225.
60. Gabay C, Msihid J, Zilberstein M, et al. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. RMD Open. 2018;4(1):e000607. doi: 10.1136/rmdopen-2017-000607
61. Dennis G, Holweg CT, Kummerfeld SK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:R90. doi: 10.1186/ar4555
62. Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499-505. doi: 10.1136/annrheumdis-2013-203923
63. Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, et al. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One. 2012;7:e40362. doi: 10.1371/journal.pone.0040362
64. Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: A pilot, prospective study. Arthritis Res Ther. 2016;18:93. doi: 10.1186/s13075-016-0995-0
65. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008;10:R50. doi: 10.1186/ar2419
66. Karsdal MA, Schett G, Emery P, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42:131-9. doi: 10.1016/j.semarthrit.2012.01.004
67. Boumans MJ, Thurlings RM, Yeo L, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71:108-13. doi: 10.1136/annrheumdis-2011-200198
68. Yasunori K, Masaaki T, Tetsuyuki N, et al. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:1093-101. doi: 10.1007/s10067-008-0870-8
69. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299-309. doi: 10.1002/art.23417
70. Boyapati A, Msihid J, Schwartzman S, et al. High baseline serum IL-6 identies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response [abstract]. Arthritis Rheum. 2018 Oct;70(Suppl 10). Available from: https://acrabstracts.org/abstract/high-baseline-serum-il-6-identifies-a-subgroup-of-rheumatoid-arthritis-patients-with-rapid-joint-damage-and-clinical-progression-and-predicts-increased-sarilumab-treatment-response/
71. Wang J, Devenport J, Low JM, et al. Relationship between base-line and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. 2016;68:882-5. doi: 10.1002/acr.22765
72. Burmester GR, Hagino O, Dong Q, et al. Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheum. 2018;70 (suppl 10). Available from: https://acrabstracts.org/abstract/unique-changes-in-hemoglobin-with-sarilumab-versus-adalimumab-are-independent-of-better-disease-control-in-patients-with-rheumatoid-arthritis-ra/
73. Genovese MC, Fleischmann R, Hagino O, et al. The effect of Sarilumab in combination with dmards on fasting glucose and glycosylated hemoglobin in patients with rheumatoid arthritis with and without diabetes [abstract]. Arthritis Rheum. 2017;69(Suppl 10).
74. Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am. 2012;38(4):727-45. doi: 10.1016/j.rdc.2012.08.019
75. Fleischmann R, Genovese MC, Lin Y, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265
76. Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol. 2013;40:768-80. doi: 10.3899/jrheum.120687
77. Kovalenko P, Paccaly A, Boyapati A, et al. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of single-dose sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA). J Pharmacokinet Pharmacodyn. 2017;44(Suppl 1):S11-S143. Abstract T-033.
78. Lok LSC, Farahi N, Juss JK et al. Effects of tocilizumab on neutrophil function and kinetics. Eur J Clin Invest. 2017;47:736-45. doi: 10.1111/eci.12799
79. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology. 2014;53:1321-31. doi: 10.1093/rheumatology/keu035
80. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology. 2014;53:2143-54. doi: 10.1093/rheumatology/keu224
81. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326-32. doi: 10.1136/annrheumdis-2014-205675
82. Liao KP, Liu J, Lu B, et al. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. Arthritis Rheum. 2015;67:2004-10. doi: 10.1002/art.39165
83. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22:147-51. doi: 10.1097/CRD.0000000000000021
84. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145-56. doi: 10.1161/CIRCRESAHA.115.306656
85. Nasonov EL, Popkova TV. Anti-inflammatory therapy for atherosclerosis: Contribution to and lessons of rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):465-73 (In Russ.). doi: 10.14412/1995-4484-2017-465-473
86. Charles-Schoeman C, St John G, Leher H, et al. The relationship between lipid profile changes and inflammation across the Phase 3 sarilumab rheumatoid arthritis (RA) development programme. Rheumatology. 2019;58(Suppl 3):kez110.062, E064. doi: 10.1093/rheumatology/kez110.062
87. Curtis JR, Lanas A, John A, et al. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res. 2012;64:1819-28. doi: 10.1002/acr.21764
88. Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30:1471-4. doi: 10.1007/s10067-011-1827-x
89. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41:645-53. doi: 10.1007/s40264-018-0651-5
90. Ungprasert P, Srivali N, Spanuchart I, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33:297-304. doi: 10.1007/s10067-014-2492-7
91. Satybaldyeva MA. Rheumatoid arthritis and venous thromboembolic events. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):456-62 (In Russ.). doi: 10.14412/1995-4484-2016-456-462
92. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
93. Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R
94. Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: A Cross Talk. Front Immunol. 2018;9:563. doi: 10.3389/fimmu.2018.00563
95. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-48. doi: 10.1038/nrclinonc.2018.8
96. Genovese MC, Kremer JM, van Vollenhoven RF et al.Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheum. 2017;69:1751-61. doi: 10.1002/art.40176
97. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715
98. Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical Guidelines]. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].
99. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-904. doi: 10.1136/annrheumdis-2013-203485
100. Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210-20. doi: 10.1093/rheumatology/kev277
101. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707-18. doi: 10.1038/nrrheum.2017
Review
For citations:
Nasonov E.L., Lila A.M. The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence. Rheumatology Science and Practice. 2019;57(5):564-577. (In Russ.) https://doi.org/10.14412/1995-4484-2019-564-57
Views:
4407
Email this article 